Calidi Biotherapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
Calidi Biotherapeutics, Inc. (CLDI) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 4.23% for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2026-08-13
- Calidi Biotherapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2026-06-30 was 4.23%, a 8.46% increase year-over-year.
- Calidi Biotherapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2025-09-30 was 3.83%, a 4.08% increase year-over-year.
- Calidi Biotherapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2025-06-30 was 3.90%, a 13.33% decline year-over-year.
- Calidi Biotherapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2025-03-31 was 4.13%, a 5.09% increase year-over-year.
- Calidi Biotherapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2025 was 3.93%, a 6.65% decline from fiscal 2024.
- Calidi Biotherapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2024 was 4.21%, a 10.50% increase from fiscal 2023.
- Calidi Biotherapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2023 was 3.81%, a 82.30% increase from fiscal 2022.
- Calidi Biotherapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2022 was 2.09%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month |
|---|---|---|---|---|
| 2026-06-30 | 4.23% 10-Q · filed 2026-08-13 | 4.23% 10-Q · filed 2026-08-13 | ||
| 2025-12-31 | 3.93% 10-K · filed 2026-03-27 | |||
| 2025-09-30 | 3.83% 10-Q · filed 2025-11-13 | 3.93% 10-Q · filed 2025-11-13 | ||
| 2025-06-30 | 3.90% 10-Q · filed 2026-08-13 | 4.06% 10-Q · filed 2026-08-13 | ||
| 2025-03-31 | 4.13% 10-Q · filed 2026-05-14 | |||
| 2024-12-31 | 4.21% 10-K · filed 2026-03-27 | |||
| 2024-09-30 | 3.68% 10-Q · filed 2025-11-13 | 4.23% 10-Q · filed 2025-11-13 | ||
| 2024-06-30 | 4.50% 10-Q · filed 2025-08-08 | |||
| 2024-03-31 | 3.93% 10-Q · filed 2025-05-14 | |||
| 2023-12-31 | 3.81% 10-K · filed 2025-03-31 | |||
| 2023-09-30 | 3.92% 10-Q · filed 2024-11-12 | 3.74% 10-Q · filed 2024-11-12 | ||
| 2023-06-30 | 3.70% 10-Q · filed 2024-08-13 | 3.73% 10-Q · filed 2024-08-13 | ||
| 2023-03-31 | 3.76% 10-Q · filed 2024-05-14 | |||
| 2022-12-31 | 2.09% 10-K · filed 2024-03-15 | |||
| 2022-09-30 | 2.98% 10-Q · filed 2023-11-14 | 2.03% 10-Q · filed 2023-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |